VANDA PHARMACEUTICALS INC. Accrued Liabilities, Current
VANDA PHARMACEUTICALS INC. (VNDA) had Accrued Liabilities, Current of $43.56 million as of 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2015-07-31
- 2015-06-30: Accrued Liabilities, Current $43.56M.
- 2015-03-31: Accrued Liabilities, Current $30.30M.
- 2014-12-31: Accrued Liabilities, Current $6.95M; Accrued Liabilities, Current as first filed $6.50M.
- 2014-09-30: Accrued Liabilities, Current $6.83M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2015-06-30 | $43.56M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $30.30M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $6.95M 10-Q · filed 2015-07-31 | $6.50M 10-K · filed 2015-03-13 |
| 2014-09-30 | $6.83M 10-Q · filed 2014-10-27 | |
| 2014-06-30 | $6.75M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $13.16M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $5.18M 10-K · filed 2015-03-13 | |
| 2013-09-30 | $4.53M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $3.77M 10-Q · filed 2013-07-31 | |
| 2013-03-31 | $3.87M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $5.19M 10-K · filed 2014-02-25 | |
| 2012-09-30 | $6.75M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $5.91M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $5.09M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $3.38M 10-K · filed 2013-02-26 | |
| 2011-09-30 | $3.41M 10-Q · filed 2011-11-07 | |
| 2011-06-30 | $2.51M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $1.32M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |